Analysts’ Recent Ratings Changes for Halozyme Therapeutics (HALO)

Halozyme Therapeutics (NASDAQ: HALO) has recently received a number of price target changes and ratings updates:

• 12/19/2025 – Halozyme Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
• 12/15/2025 – Halozyme Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Halozyme Therapeutics was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 12/6/2025 – Halozyme Therapeutics was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/4/2025 – Halozyme Therapeutics had its “sell” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
• 12/1/2025 – Halozyme Therapeutics had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Halozyme Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
• 11/19/2025 – Halozyme Therapeutics had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Halozyme Therapeutics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $56.00. They now have a “neutral” rating on the stock.
• 11/16/2025 – Halozyme Therapeutics was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/13/2025 – Halozyme Therapeutics had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Halozyme Therapeutics was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/7/2025 – Halozyme Therapeutics was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b)” rating.
• 11/4/2025 – Halozyme Therapeutics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 11/4/2025 – Halozyme Therapeutics had its price target raised by analysts at Citizens Jmp from $91.00 to $92.00. They now have a “market outperform” rating on the stock.
• 10/27/2025 – Halozyme Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $63.00 to $65.00. They now have a “neutral” rating on the stock.
• 10/25/2025 – Halozyme Therapeutics was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction dated Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the transaction, the chief operating officer directly owned 12,737 shares in the company, valued at $830,325.03. This trade represents a 25.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 85,661 shares of company stock worth $6,036,837. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.